Poliovirus Therapy for Recurrent Glioblastoma Has 3-Year Survival Rate of 21%
Phase 1 study of Duke therapy shows long-term survival benefit for a lethal cancer
A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.
Comparatively, just 4 percent of patients at Duke with the same type of recurring brain tumors were alive at three years when undergoing the previously available standard treatment.
Click here to read more.
Calendar/Courses
9th World Congress of Neuroendoscopy
Nov. 21-24, 2019; Orlando, Fla.
Medical and Surgical Interventions in ICH: A Practical Workshop
Nov. 23, 2019; Chicago
2nd International Conference on Brain Stimulation
Nov. 27-28, 2019; Dubai, United Arab Emirates
2019 AANS/CNS Section on Pediatric Neurological Surgery Annual Meeting
Dec. 5-8, 2019; Scottsdale, Ariz.
AANSIM 2019
Dec. 5-8, 2019; Mumbai, India
